- Home
- PNR vs SYRE Comparison
PNR vs SYRE Comparison
Compare PNR & SYRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PNR | SYRE |
|---|---|---|
| Founded | 1966 | 2013 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.5B | 7.6B |
| IPO Year | 2003 | 2015 |
Fundamental Metrics
Financial Performance| Metric | PNR | SYRE |
|---|---|---|
| Price | $52.71 | $85.08 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 17 | 18 |
| Target Price | $71.47 | ★ $119.93 |
| AVG Volume (30 Days) | ★ 2.3M | 1.4M |
| Earning Date | 10-27-2026 | 11-03-2026 |
| Dividend Yield | ★ 2.02% | N/A |
| EPS Growth | ★ 5.88 | N/A |
| EPS | ★ 1.05 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $17.85 | N/A |
| P/E Ratio | $50.91 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $51.13 | $21.15 |
| 52 Week High | $111.94 | $110.18 |
Technical Indicators
Market Signals| Indicator | PNR | SYRE |
|---|---|---|
| Relative Strength Index (RSI) | 36.36 | 48.96 |
| Support Level | $51.13 | $82.86 |
| Resistance Level | $76.12 | $94.10 |
| Average True Range (ATR) | 1.21 | 4.94 |
| MACD | 0.38 | 0.01 |
| Stochastic Oscillator | 43.34 | 48.24 |
Price Performance
Historical ComparisonAbout PNR Pentair plc.
Pentair is a global leader in the water treatment industry, with 10,000 employees and a presence in 25 countries. Its business is organized into three segments: pool, water technologies, and flow. The company offers a wide range of water solutions, including energy-efficient swimming pool equipment, filtration solutions, and commercial and industrial pumps. Pentair generated approximately $4.2 billion in revenue in 2025.
About SYRE Spyre Therapeutics Inc.
Spyre Therapeutics Inc is a clinical-stage biotechnology company pioneering long-acting antibodies and antibody combinations to redefine the standard of care for inflammatory bowel disease (IBD) and rheumatic diseases. Spyre's pipeline includes extended half-life antibodies targeting α4β7, TL1A, and IL-23 in development as monotherapies and pair-wise combinations. It has a single reportable segment, which is the development of biopharmaceutical products for the treatment of patients with IBD and other immune-mediated disease.